OR WAIT null SECS
Contract service providers must step up their game to stay competitive in increasingly complex bio/pharma market.
The need for preclinical testing expertise is growing as molecular complexity increases.
A look at the newest innovations offers a deeper understanding of affinity ligands and their role in the future of downstream processing.
January 11, 2022
The agreeement will add to Merck KGaA’s LNP and mRNA capabilities.
January 07, 2022
The acquisition of Protein Metrics expands Insightful Science’s R&D solutions to include proteomics.
January 05, 2022
With this investment into Yapan Bio, Piramal Pharma adds new technologies and capabilities in large molecules, including vaccines and gene therapies, to its global offering.
Particle analysis provides assurances of the quality and performance of the final dosage form in pharmaceutical development.
January 03, 2022
A new focus on speed to market creates challenges for facility design and construction.
January 02, 2022
Recent developments in the outsourcing industry include a focus on early development services, biosimilar production, and RNA technology.
December 16, 2021
FUJIFILM Irvine Scientific’s new manufacturing facility in Tilburg, the Netherlands, is now fully operational.
FUJIFILM Diosynth Biotechnologies plans to invest £400 million (US$528 million) to expand its Billingham, Teeside facility in the United Kingdom.
December 09, 2021
Lonza has signed a five-year services agreement to provide for the development and manufacturing of biologics and small molecules for portfolio companies owned by Bioqube Ventures.
Leucid Bio will collaborate with Lonza to use Lonza’s Cocoon Platform for clinical and commercial manufacturing of CAR T cells for Leucid’s lead candidate.